4D Molecular Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

• 4D Molecular Therapeutics Inc FDMT.OQ reported a quarterly adjusted loss of 79 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -75 cents. The mean expectation of ten analysts for the quarter was for a loss of 70 cents per share. Wall Street expected results to range from -80 cents to -57 cents per share.

• Revenue fell 100% to $1.00 thousand from a year ago; analysts expected $1.71 million.

• 4D Molecular Therapeutics Inc's reported EPS for the quarter was a loss of 79 cents​.

• The company reported a quarterly loss of $43.84 million.

• 4D Molecular Therapeutics Inc shares had fallen by 19.6% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for 4D Molecular Therapeutics Inc is $37.50

This summary was machine generated from LSEG data February 28 at 11:58 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)